We have an exciting opportunity to join our team at Oxford university as a Postdoctoral scientist. @CmdOxford@asap_discovery@covid_moonshot
https://t.co/ht9VKPBy0V
I pinch myself, but it stays unreal... 2 years ago we cobbled up something in desperation, and now we get to be one of the AViDD Centers! @XChem_DLS is deep in the mix: new methods, piles of open data. All groups are recruiting, check https://t.co/57dxoIKr2N, or get in touch.
A consortium led by scientists from @covid_moonshot receives NIH funding to discover & develop globally accessible and affordable oral antivirals for #COVID19 & future pandemics. We're proud to be part of this global #openscience consortium! https://t.co/Sn7g9CovTV
We’ve been silent for a while. Sorry about that. However, we have some very exciting news and we’ll dovetail that with a quick status update…
Today, members of COVID Moonshot have successfully secured an NIH grant with initial funding of $68M to help prevent pandemics!
I cry for England 🏴—#BA2 hospitalizations have now exceeded old #Omicron’s peak—which were **merely 3 months ago**. So much for stupid mass infection natural herd strategy.
This is @borisjohnson & @sajidjavid’s horrible British 🇬🇧 exceptionalism.
HT @Antonio_Caramia#COVID19
Reinfection data! Study tracking >300k people found reinfections were rare (<500/month) until Nov '21, but increased to >4500/month in Jan '22.
19% of 1st infections, 17% of 2nd, & 25.9% of 3rd were hospitalized. (But only PCR, no home tests counted).
https://t.co/b9rB4HOrGy 1/
An important interview with @griffen_ed just out in @medicine_maker on how key Moonshot partners like @EnamineLtd are being affected by the war in Ukraine and its broader impact on our industry. @AngusLikesWords
https://t.co/cvogdLLgqn
My friends and colleagues @EnamineLtd in Kyiv are outstanding members of the @covid_moonshot team. They are part of our effort to deliver safe, effective, generic anti-virals to treat COVID-19 globally, but their safety, that of their families & all Ukrainians matters more.
Online Today! Looking beyond the blood...our review of mucosal immune responses in COVID19. Already out of date because it was submitted in Nov, but it's a living review! We will be updating as the field develops. https://t.co/aHmGYZnXat
Today we're delighted to share a significant milestone in Moonshot’s journey towards an open-science COVID antiviral: We have identified compounds meeting our criteria for progression to preclinical evaluation!
A core principle behind COVID Moonshot is that an open-science approach will accelerate antiviral discovery. With this weekend's release of a new preprint from @SHIONOGI_JP describing an extraordinary new noncovalent oral antiviral, this hypothesis has been validated!
Okay, final tweet of the year. Excited to show our lead series is potent against Alpha, Beta and Omicron variants! This is why antivirals are complementary to vaccines in getting us out of this pandemic.
@MedChemica@PostEra_AI@jchodera@DiamondLightSou@london_lab@DNDi
Breaking News: Pfizer said its pill to treat Covid-19 had been found to be highly effective at preventing severe illness among at-risk people. It appears to be more effective than a similar offering from Merck, which is awaiting U.S. authorization. https://t.co/v89RrXaAKq
@london_lab@covid_moonshot The @covid_moonshot project just received key funding from @wellcometrust to put the most promising drug candidates into clinical trials. We hope the first drugs will be available at the end of 2022. All our results will be publicly shared and free for anyone to use. (3/3)
Last year, a simple tweet started the 1st #openscience global effort to design affordable, straight-to-generic #COVID19 antivirals from scratch. Today, the @covid_moonshot project has received key funding from @wellcometrust to put these drugs into trials. https://t.co/QJgFkrMJcm